Patent application number | Description | Published |
20080249283 | Hla-Binding Peptides, Precursors Thereof, Dna Fragments and Recombinant Vectors that Code for Those Peptide Sequences - An HLA-binding peptide binding to an HLA-A type molecule, said HLA-binding peptide comprising at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 183, and not less than 8 and not more than 11 amino acid residues is provided. Any of the amino acid sequence is predicted to have the binding property to a HLA-A type molecule by a predicting program using an active learning experiment method as illustrated in FIG. | 10-09-2008 |
20080293916 | Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding Peptide - An HLA-binding peptide binding to an HLA-A type molecule, said HLA-binding peptide comprising at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 60, and not less than 8 and not more than 11 amino acid residues is provided. Any of the amino acid sequence is predicted to have the binding property to a human HLA-A24 molecule or a human HLA-A2 molecule by a predicting program using an active learning experiment method as illustrated in FIG. | 11-27-2008 |
20080306243 | Hla-Binding Peptide, and Dna Fragment and Recombinant Vector Coding for Said Hla-Binding Peptide - An HLA-binding peptide binding to an HLA-A type molecule is provided that includes at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 30, and not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences are amino acid sequences predicted to bind to a human HLA-A molecule using a prediction program employing an active learning experiment method shown in FIG. | 12-11-2008 |
20090023895 | HLA-BINDING PEPTIDE, PRECURSOR THEREOF, AND DNA FRAGMENT AND RECOMBINANT VECTOR CODING FOR SAID HLA-BINDING PEPTIDE - An HLA-binding peptide binding to an HLA-A type molecule is provided that includes one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 52, and not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences are amino acid sequences predicted to bind to a human HLA-A molecule using a prediction program employing an active learning experiment method shown in FIG. | 01-22-2009 |
20100322968 | THERAPEUTIC AGENT FOR CANCER - The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses. | 12-23-2010 |
20110060124 | HLA-BINDING PEPTIDES, PRECURSORS THEREOF, DNA FRAGMENTS AND RECOMBINANT VECTORS THAT CODE FOR THOSE PEPTIDE SEQUENCES - An HLA-binding peptide binding to an HLA-A type molecule, said HLA-binding peptide comprising at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 183, and not less than 8 and not more than 11 amino acid residues is provided. Any of the amino acid sequences is predicted to have the binding property to a human HLA-A type molecule by a predicting program using an active learning experiment method as illustrated in FIG. | 03-10-2011 |
20110087005 | HLA-BINDING PEPTIDE, PRECURSOR THEREOF, AND DNA FRAGMENT AND RECOMBINANT VECTOR CODING FOR SAID HLA-BINDING PEPTIDE - An HLA-binding peptide binding to an HLA-A type molecule is provided that includes one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 52, and not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences are amino acid sequences predicted to bind to a human HLA-A molecule using a prediction program employing an active learning experiment method shown in FIG. | 04-14-2011 |
20110206711 | METHOD FOR INDUCING CYTOTOXIC T-CELLS, CYTOTOXIC T-CELL INDUCER, AND PHARMACEUTICAL COMPOSITION AND VACCINE EMPLOYING SAME - A method for inducing cytotoxic T-cells that includes binding to an HLA molecule on the surface of a cell that is a target of a cytotoxic T-cell a peptide containing one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 13 and consisting of not less than 8 and not more than 11 amino acid residues, or a peptide derived from a precursor thereof. | 08-25-2011 |
20140341939 | MODIFICATION OF HELPER T CELL-INDUCING POLYPEPTIDE - The present invention provides a tumor antigen-specific Th-inducing polypeptide capable of efficient antigen presentation, and an antitumor agent using same. | 11-20-2014 |
20150087809 | HLA-BINDING PEPTIDES, PRECURSORS THEREOF, DNA FRAGMENTS AND RECOMBINANT VECTORS THAT CODE FOR THOSE PEPTIDE SEQUENCES - An HLA-binding peptide binding to an HLA-A type molecule, said HLA-binding peptide comprising at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 183, and not less than 8 and not more than 11 amino acid residues is provided. Any of the amino acid sequence is predicted to have the binding property to a human HLA-A type molecule by a predicting program using an active learning experiment method as illustrated in FIG. | 03-26-2015 |
Patent application number | Description | Published |
20100144025 | HLA-BINDING PEPTIDE, PRECURSOR THEREOF, DNA FRAGMENT AND RECOMBINANT VECTOR ENCODING THE SAME - There is provided an HLA-binding peptide being excellent in binding affinity to an HLA-A type molecule. An HLA-binding peptide capable of binding to an HLA-A type molecule, including one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 50, and being composed of 8 or more and 11 or less amino acid residues, is provided. All of the amino acid sequences are the amino acid sequences that are predicted to be capable of binding to an HLA-A molecule by using a prediction program utilizing an active learning method shown in FIG. | 06-10-2010 |
20100255020 | METHOD FOR INDUCING CYTOTOXIC T-CELLS, CYTOTOXIC T-CELL INDUCERS, AND PHARMACEUTICAL COMPOSITIONS AND VACCINES EMPLOYING THEM - A method for inducing cytotoxic T-cells is provided that includes binding to an HLA molecule on the surface of a cell that is a target of a cytotoxic T-cell, a peptide containing one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 2, and 3 and composed of not less than 8 and not more than 11 amino acid residues, or a peptide derived from a precursor thereof. | 10-07-2010 |
20140094586 | HLA-BINDING PEPTIDE, AND DNA FRAGMENT AND RECOMBINANT VECTOR CODING FOR SAID HLA-BINDING PEPTIDE - An HLA-binding peptide binding to a HLA-A type molecule, the HLA-binding peptide includes at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 80, and consists of not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences herein mentioned are the predicted amino acid sequences binding to a human HLA-A type molecule with the prediction program using the certain active learnig method. | 04-03-2014 |